The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
Drug Safety-related Labeling Changes (SrLC) Database
ANDA
Abbreviated New Drug Application
BLA
Biologics License Application
CDER
Center for Drug Evaluation and Research
MG
Medication Guide
NDA
New Drug Application
PCI
Patient Counseling Information
PI
Patient Information
PLR
Physician Labeling Rule
PLLR
Pregnancy and Lactation Labeling Rule
Italics
For the most part, italics indicate an FDA comment such as:
Additions and/or revisions underlined
These italics usually appear at the beginning of the section.
In some cases, italics may be an inherent part of the label, and will most often appear in the body of the section.
Underlines
Any text that is underlined indicates text that has been added or revised. There are exceptions where underlining occurs in a section subtitle or heading. This is the case when there is just one word underlined in the body of the text.
Sections
BW
Box Warning
WP
Warnings and Precautions all in one section (PLR-format)
Warnings as one section (pre-PLR format)
Precautions as one section (pre-PLR format)
AR
Adverse Reactions (in pre-PLR format, this may be a subheading under precautions).
DI
Drug Interactions (in pre-PLR format, this may be a subheading under precautions).
USP
Use in Specific Populations
(Inclusive on one or more of the following: Pregnancy; Lactation (PLLR- format); Nursing Mothers (pre-PLLR format); Females and Males of Reproductive Potential (PLLR format only); Pediatric Use, Geriatric Use, Renal Impairment, Hepatic Impairment, Sex, Race (these last six may be a subheading of precautions if label in pre-PLLR format.
PCI/PI/MG
Patient Counseling Information (PLR format only) - summarizes the information that a health care provider should convey to a patient (or caregiver when applicable) when a counseling discussion is taking place (e.g., a physician prescribing a drug during an office visit, a nurse providing discharge instructions at a hospital, or a pharmacist conveying information at a pharmacy).
Patient Information - FDA approved patient labeling.
Medication Guide - paper handouts that come with many prescription medicines. The guides address issues that are specific to particular drugs and drug classes, and they contain FDA-approved information that can help patients avoid serious adverse events.
Only NDAs and CDER regulated BLAs are included in this database. ANDAs are not included.
Applications that remain active, even if the product has been discontinued, undergo safety-related labeling changes.
The Drug Safety-related Labeling Changes (SrLC) database provides approved safety-related labeling changes from January 2016 forward.
Data prior to January 2016 will continue to be available on the
MedWatch website.
There are two ways to search: a Drug Name Search and a Date Search.
OR
Questions related to the drug data in these files should be directed to the Center for
Drug Evaluation and Research, Division of Drug Information druginfo@fda.hhs.gov.